HWG Holdings’s Vertex Pharmaceuticals VRTX Stock Holding History

HWG Holdings’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,100	Closed	-$260K	–	123
2020 Q4	$260K	Buy	+1,100	New	+$252K	0.13%	65

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

HWG Holdings's VRTX Position: Q4 2024 in Review

HWG Holdings sold out of Vertex Pharmaceuticals (VRTX) in Q4 2024, closing a stake of 2,278 shares — an estimated $1.06M sold.

HWG Holdings first reported a position in VRTX in Q4 2018 and held it in 11 quarters. The position peaked at $2.51M in Q2 2020. 1,557 funds tracked by Wall St. Rank hold VRTX as of Q4 2024.

HWG Holdings reported no remaining Vertex Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
HWG Holdings sold 2,278 Vertex Pharmaceuticals shares in Q4 2024, an estimated $1.06M.
HWG Holdings first reported a position in Vertex Pharmaceuticals in Q4 2018 and held it in 11 quarters.
HWG Holdings's Vertex Pharmaceuticals position peaked at $2.51M in Q2 2020.
1,557 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2024.

Based on HWG Holdings's 13F filing for Q4 2024, filed 27 Feb 2025.